

Cara Therapeutics, Inc.
Form 8-K
June 16, 2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 15, 2016

CARA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction

of incorporation)

001-36279
(Commission

File Number)

75-3175693
(IRS Employer

Identification No.)

4 Stamford Plaza

Edgar Filing: Cara Therapeutics, Inc. - Form 8-K

107 Elm Street

Stamford, Connecticut 06902
(Address of principal executive offices)

Registrant's telephone number, including area code (203) 406-3700

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2.):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07.Submission of Matters to a Vote of Security Holders.

On June 15, 2016, Cara Therapeutics, Inc. (the Company) held its Annual Meeting of Stockholders (Annual Meeting). At the Annual Meeting, the Company's stockholders voted on the two proposals set forth below. A more detailed description of each proposal is set forth in the Company's Proxy Statement filed with the Securities and Exchange Commission on April 27, 2016.

Proposal 1 Election of Directors

Dr. Jeffrey L. Ives and Mr. Dean Slagel were elected to serve as directors of the Company's Board of Directors until the 2019 Annual Meeting of Stockholders and until their successors are duly elected or until their earlier resignation or removal, by the following votes:

Nominee	Votes For	Votes Withheld	Broker Non-Votes
Dr. Jeffrey L. Ives	9,580,306	4,067,985	6,036,363
Mr. Dean Slagel	5,844,282	7,804,009	6,036,363

Proposal 2 Ratification of the Selection of Independent Registered Public Accounting Firm

The stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2016, by the following votes:

Votes For	Votes Against	Votes Abstain
17,414,828	2,268,122	1,704

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CARA THERAPEUTICS, INC.

By: /s/ Josef Schoell
Josef Schoell
Chief Financial Officer
(Principal Financial and Accounting
Officer)

Date: June 16, 2016